Navigation Links
AFFiRiS AG: Atherosclerosis Vaccine Development Receives EU Support
Date:5/27/2009

% - and that's only if the patient takes the necessary medication correctly and regularly. In contrast, our vaccine approach aims at decreasing the cholesterol transfer from HDL to LDL, thus increasing the concentration of the beneficial HDL. This vaccine approach with its long-lasting effects should avoid patients having to take life-long, daily medication to a strict regimen."

The main item of the joint efforts of AFFiRiS and EMC is the vaccination against cholesteryl ester transfer protein (CETP). By transferring cholesteryl ester from HDLc to LDLc and VLDLc, this protein reduces "good" HDL and has a detrimental impact on the ratio of LDLc to HDLc. In the future, our vaccine will reduce the activity of this protein and shift the balance of HDLc and LDLc in the blood back in favour of HDLc.

Outlining the major benefit of the AFFITOME(R) technology, project manager Dr. Sylvia Brunner adds: "CETP is one of the body's own proteins. Trying to reduce its activity using a vaccine, we are faced with a formidable challenge. The body has many means of suppressing an immune response to its own proteins, or limiting the effectiveness of any such response. That's why previous attempts to develop a vaccine against CETP failed. However, as AFFiRiS has already demonstrated in its work on a vaccine for Alzheimer's disease, the AFFITOME(R) technology makes it possible to circumvent these mechanisms. We are now applying this principle to atherosclerosis."

CEO Dr. Walter Schmidt continues: "So far, we have announced the development of vaccines for three diseases - Alzheimer's, Parkinson's and now atherosclerosis. Currently, four other indications are also part of our development pipeline, all of them characterised by a very high number of patients but also by a lack of satisfactory treatments. As a result, these indications fit in well with our long-term strategy. Our strategy itself is beginning to pay back as demons
'/>"/>

SOURCE AFFiRiS AG
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. GlaxoSmithKline and AFFiRiS Sign an Exclusive Licence and Option Agreement for Therapeutic Alzheimers Disease Candidate Vaccines
2. AFFiRiS - MIG-Fonds Increases Investment by Euro 3 Million
3. Research Published in Nature Medicine Shows Disruption of Chemokine Interactions Inhibits Atherosclerosis in Mice
4. Interleukin Genetics to Present New Findings at the 11th Cardiovascular Genomics and Atherosclerosis Symposium
5. Old and new therapies combine to tackle atherosclerosis
6. Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate
7. ImmunoVaccine Technologies Partners with FIT Biotech to advance a therapeutic HIV vaccine
8. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imaging
9. ImmunoVaccine Technologies Collaborates with NRC Institute for Biodiagnostics Atlantic to measure effectiveness of DepoVax(TM) with novel MRI Imagin
10. Professor Hanna Nohynek Joins Encorium as Head Consultant of its Clinical Vaccine Research Team
11. Novavax Announces Enrollment in the Second Phase II Study of its Seasonal Influenza VLP Vaccine Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... Dec. 22, 2014  ( www.competitivehealth.com ) — Competitive ... medical bill review and advocacy service, has signed an ... WellCard Savings discount health services marketplace. 63% ... more than they expected to pay. As part of ... costs, WellCard Savings is pleased to offer medical bill ...
(Date:12/22/2014)... 22, 2014 Fertility Associates of Memphis ... Bank USA , a network of more than 20 ... partnership, patients have fast access to a national pool ... IVF . Fertility Associates of Memphis is the only ... treatment option. , Dr. William Kutteh , director ...
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one ... of Nick Maroulis, Pharm.D. to the newly created position ... In this position, Dr. Maroulis will continue to manage ... of our multi-site pharmacies as the company expands. Dr. ... that time he has served in many different capacities ...
(Date:12/19/2014)... Dec. 19, 2014 Bina Technologies, Inc. (Bina, ... that they have been acquired by Roche (SIX: RO, ... privately held company that provides a big data platform ... (NGS) data for the academic and translational research markets. ... and will continue to focus on development of their ...
Breaking Biology Technology:WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 2Fertility Associates of Memphis Announces Partnership with Donor Egg Bank USA 3BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Bina Technologies is acquired by Roche. 2Bina Technologies is acquired by Roche. 3
... Million to $247 Million -, Third Quarter 2008 Highlights:, -- ... 2007 -- Total revenues without Osteocel of $62.5 million; up 62.3% ... -- Gross profit of $54.7 million; up 73.2% from the third quarter ... in the third quarter of 2007, -- GAAP loss per ...
... Alert Limited,(OTC Bulletin Board: DYMC) (the "Company") is ... medical cannabis-based,pharmaceutical products. Today the Company is pleased ... all of the assets of Cannex, a privately,owned ... political,activist Steven W. Kubby (http://www.kubby.com ). The ...
... At CHEST 2008, PARI,Respiratory Equipment will ... breath-enhanced nebulizers and their in-vitro,performance and delivery ... "Our goal in testing various breath-enhanced ... delivery rate to ensure patients,receive clinically effective ...
Cached Biology Technology:Nuvasive Reports Third Quarter 2008 Financial Results 2Nuvasive Reports Third Quarter 2008 Financial Results 3Nuvasive Reports Third Quarter 2008 Financial Results 4Nuvasive Reports Third Quarter 2008 Financial Results 5Nuvasive Reports Third Quarter 2008 Financial Results 6Nuvasive Reports Third Quarter 2008 Financial Results 7Nuvasive Reports Third Quarter 2008 Financial Results 8Nuvasive Reports Third Quarter 2008 Financial Results 9Nuvasive Reports Third Quarter 2008 Financial Results 10Nuvasive Reports Third Quarter 2008 Financial Results 11Nuvasive Reports Third Quarter 2008 Financial Results 12Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 2Dynamic Signs Asset Acquisition Deal With Cannex and Brings Onboard Leading Medical Cannabis Research Scientist Dr. Robert Melamede, Former Chairman of the Biology Department, University of Colorado 3
(Date:12/5/2014)... MOUNTAIN VIEW, Calif. , Dec. 4, 2014 ... and safety has boosted investments in new testing ... products has also given rise to a range ... driven by the requirements of Generation Y, which ... digital technologies. As a result, product development strategies ...
(Date:12/3/2014)... GLENDALE, Ariz. , Dec. 2, 2014 ... biometric hand readers, Inception Technologies is pleased to announce ... it easier for customers to collect the workforce data ... the problems that have been left by existing readers. ... to user interface, connectivity and modern technology. Older models ...
(Date:11/21/2014)... -- C-Labs LLC, a leading provider of remote and ... announced the appointment of John Traynor to ... advisor to the firm, Mr. Traynor will now oversee ... out of the C-Labs office in Redmond, ... , Chief Executive Officer. Photo - ...
Breaking Biology News(10 mins):Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 2Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 3Emerging Technologies Enable Smarter Monitoring of Assets, Push Industrial Testing, Inspection and Monitoring Market 4Inception Technologies to Release New Biometric Reader 2C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2
... BOSTON (3:00 p.m. ET, November 1, 2010) A ... may provide a new approach to cancer treatment, according ... Proceedings of the National Academy of Sciences ... inhibitors), limited tumor growth in mice by inducing cell ...
... The rate at which lead poisoning has struck young Rhode ... a Brown University-led geographic analysis of comprehensive health department data ... cases of lead poisoning, researchers have been able to help ... that 12-year period, some census blocks in the state had ...
... as a large-scale, emission-free energy source, bat and bird ... annually. Migratory bats, such as the hoary bat, are ... they fly their routes in the forested ridges of ... immediate area, but is also detrimental to ecosystem health ...
Cached Biology News:Of 50,000 small molecules tested to fight cancer, 2 show promise 2Lead poisoning maps in R.I. reveal huge disparities, guide cleanup 2Slight change in wind turbine speed significantly reduces bat mortality 2
Anti-Wnt-2 Polyclonal Antibody Description: 100 g purified goat polyclonal antibody. Reacts with human/mouse/rat. Tested in Western blot/IP/IHC. Research Focus: signal transduction Storage...
... custom microplate coating using advanced automated high throughput microplate processing ... We can also accommodate virtually any lot size of the ... , 8 and 12 well ... 384 well microplate, ...
...
... Mynox is the first ... by killing them, and not ... is the only anti-mycoplasma agent ... clean virus stocks directly. The ...
Biology Products: